In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sciclone Pharmaceuticals Inc (NASDAQ:SCLN) reported that Man Group Plc has picked up 2,837,565 of common stock as of 2017-07-27.
The acquisition brings the aggregate amount owned by Man Group Plc to a total of 2,837,565 representing a 5.48% in the company.
For those not familiar with the company, SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.
A glance at Sciclone Pharmaceuticals Inc (NASDAQ:SCLN)’s key stats reveals a current market capitalization of 566.47M based on 51.73M shares outstanding and a price at last close of $10.95. per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2014-08-15, Chang picked up 25,040 at a purchase price of $$6.00 per share.This brings their total holding to 25,040 as of the date of the filing.
On the sell side, the most recent transaction saw Blobel unload 7,390 shares at a sale price of $11.00. This brings their total holding to 122,209.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Sciclone Pharmaceuticals Inc (NASDAQ:SCLN) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.